247 related articles for article (PubMed ID: 32647911)
21. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.
Nakamura Y; Hozawa S; Sagara H; Ohbayashi H; Lee LA; Crawford J; Tamaoki J; Nishi T; Fowler A
Curr Med Res Opin; 2021 Sep; 37(9):1657-1665. PubMed ID: 34162298
[TBL] [Abstract][Full Text] [Related]
22. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
Siler TM; Donald AC; O'Dell D; Church A; Fahy WA
Int J Chron Obstruct Pulmon Dis; 2016; 11():971-9. PubMed ID: 27274218
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
McCormack M; Paczkowski R; Gronroos NN; Noorduyn SG; Lee L; Veeranki P; Johnson MG; Igboekwe E; Kahle-Wrobleski K; Panettieri R
Adv Ther; 2024 Mar; 41(3):1245-1261. PubMed ID: 38310193
[TBL] [Abstract][Full Text] [Related]
24. InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions.
Bourdin A; Criner G; Devouassoux G; Dransfield M; Halpin DMG; Han MK; Jones CE; Kalhan R; Lange P; Lettis S; Lipson DA; Lomas DA; Echave-Sustaeta María-Tomé JM; Martin N; Martinez FJ; Quasny H; Sail L; Siler TM; Singh D; Thomashow B; Watz H; Wise R; Hanania NA
Chronic Obstr Pulm Dis; 2021 Jan; 8(1):76-90. PubMed ID: 33156982
[TBL] [Abstract][Full Text] [Related]
25. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
Pascoe S; Barnes N; Brusselle G; Compton C; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Hartley B; Lange P; Lettis S; Lipson DA; Lomas DA; Martinez FJ; Papi A; Roche N; van der Valk RJP; Wise R; Singh D
Lancet Respir Med; 2019 Sep; 7(9):745-756. PubMed ID: 31281061
[TBL] [Abstract][Full Text] [Related]
26. COPD exacerbation costs in the IMPACT study: a within-trial analysis.
Bogart MR; Hopson SD; Shih HC; Stanford RH; Coutinho AD
Am J Manag Care; 2020 May; 26(5):e150-e154. PubMed ID: 32436683
[TBL] [Abstract][Full Text] [Related]
27. Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT.
Dransfield MT; Crim C; Criner GJ; Day NC; Halpin DMG; Han MK; Jones CE; Kilbride S; LaFon D; Lipson DA; Lomas DA; Martin N; Martinez FJ; Singh D; Wise RA; Lange P
Ann Am Thorac Soc; 2021 May; 18(5):788-798. PubMed ID: 33108212
[No Abstract] [Full Text] [Related]
28. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
[TBL] [Abstract][Full Text] [Related]
29. Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD.
Bansal S; Anderson M; Anzueto A; Brown N; Compton C; Corbridge TC; Erb D; Harvey C; Kaisermann MC; Kaye M; Lipson DA; Martin N; Zhu CQ; Papi A
NPJ Prim Care Respir Med; 2021 May; 31(1):29. PubMed ID: 34035312
[TBL] [Abstract][Full Text] [Related]
30. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study.
Mannino D; Bogart M; Wu B; Germain G; Laliberté F; MacKnight SD; Jung Y; Stiegler M; Duh MS
Respir Med; 2022 Jun; 197():106807. PubMed ID: 35429764
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of fluticasone furoate/umeclidinium bromide/vilanterol and umeclidinium bromide/vilanterol in the management of moderate and severe COPD in China.
Zhou Y; Duan S; Zhang L; Peng F
Respir Med; 2024 May; 226():107632. PubMed ID: 38621548
[TBL] [Abstract][Full Text] [Related]
32. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
Hanania NA; Bunner SH; Bengtson LGS; Ismaila AS; Bogart M
Int J Chron Obstruct Pulmon Dis; 2023; 18():407-418. PubMed ID: 36998390
[TBL] [Abstract][Full Text] [Related]
33. The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
Lee L; Kerwin E; Collison K; Nelsen L; Wu W; Yang S; Pascoe S
Respir Med; 2017 Oct; 131():148-157. PubMed ID: 28947022
[TBL] [Abstract][Full Text] [Related]
34. The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial.
Han MK; Criner GJ; Dransfield MT; Halpin DMG; Jones CE; Kilbride S; Lange P; Lettis S; Lipson DA; Lomas DA; Martin N; Wise RA; Singh D; Martinez FJ
Am J Respir Crit Care Med; 2020 Nov; 202(9):1237-1243. PubMed ID: 32584168
[No Abstract] [Full Text] [Related]
35. Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
Mehta R; Farrell C; Hayes S; Birk R; Okour M; Lipson DA
Clin Pharmacokinet; 2020 Jan; 59(1):67-79. PubMed ID: 31321713
[TBL] [Abstract][Full Text] [Related]
36. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
[TBL] [Abstract][Full Text] [Related]
37. The effect of exacerbation history on outcomes in the IMPACT trial.
Halpin DMG; Dransfield MT; Han MK; Jones CE; Kilbride S; Lange P; Lipson DA; Lomas DA; Martinez FJ; Pascoe S; Singh D; Wise R; Criner GJ
Eur Respir J; 2020 May; 55(5):. PubMed ID: 32299860
[TBL] [Abstract][Full Text] [Related]
38. Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial.
Thompson PJ; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Lipson DA; Maghzal GJ; Martinez FJ; Midwinter D; Singh D; Tombs L; Wise RA
Respirology; 2022 Dec; 27(12):1034-1044. PubMed ID: 35970518
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study.
Rothnie KJ; Wood RP; Czira A; Banks VL; Camidge LJ; Massey OKI; Seif M; Compton C; Sharma R; Halpin DMG; Ismaila AS; Vogelmeier CF
BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38772900
[TBL] [Abstract][Full Text] [Related]
40. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
Feldman GJ; Sousa AR; Lipson DA; Tombs L; Barnes N; Riley JH; Patel S; Naya I; Compton C; Alcázar Navarrete B
Adv Ther; 2017 Nov; 34(11):2518-2533. PubMed ID: 29094315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]